Methylenetetrahydrofolate reductase (MTHFR) genetic variation and major depressive disorder prognosis: A five-year prospective cohort study of primary care attendees

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 165, Issue 1, 2014, Pages 68-76

  Bousman, Chad A ^a,b   Potiriadis, Maria ^a   Everall, Ian P ^a   Gunn, Jane M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Biomarker; Depression; Gene; Trajectories

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GENETIC MARKER; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DSM-IV; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; AGED; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYMOLOGY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY HEALTH CARE; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHOLOGICAL TESTS; QUESTIONNAIRES; YOUNG ADULT;

EID: 84890238642     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32209     Document Type: Article

References (58)

1. Almeida OP, Flicker L, Lautenschlager NT, Leedman P, Vasikaran S, van Bockxmeer FM. 2005. Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 26(2):251-257.
2. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. 2008. Homocysteine and depression in later life. Arch Gen Psychiatry 65(11):1286-1294.
3. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. 2000. Nutrition and depression: Focus on folate. Nutrition 16(7-8):544-546.
4. American Psychiatric Association. 1994. Diagnostic criteria from DSM-IV. Washington, DC: The Association. 358 p.
5. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. 2003. Folate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression: The Hordaland Homocysteine Study. Arch Gen Psychiatry 60(6):618-626.
6. Boardman F, Griffiths F, Kokanovic R, Potiriadis M, Dowrick C, Gunn J. 2011. Resilience as a response to the stigma of depression: A mixed methods analysis. J Affect Disord 135(1-3):267-276.
7. Botto LD, Yang Q. 2000. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 151(9):862-877.
8. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. 1998. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 98(23):2520-2526.
9. Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B, de Dios Luna J, Lorente JA, de Diego-Otero Y, King M, et al. 2006. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: The PREDICT-gene study. Am J Med Genet Part B 141B(8):912-917.
10. Clemente C, Tsiantis J, Kolvin I, Ba G, Christogiorgos S, Lee C, Taylor B, Miller R. 2003. Social adjustment in three cultures: Data from families affected by chronic blood disorders. A sibling study. Haemophilia 9(3):317-324.
11. Cohen J. 1992. A power primer. Psychol Bull 112(1):155-159.
12. Colman I, Naicker K, Zeng Y, Ataullahjan A, Senthilselvan A, Patten SB. 2011. Predictors of long-term prognosis of depression. CMAJ 183(17):1969-1976.
13. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. 2005. Efficiency and power in genetic association studies. Nat Genet 37(11):1217-1223.
14. Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, Casey P, Wilkinson C, Vazquez-Barquero JL, Wilkinson G. 2000. Problem solving treatment and group psychoeducation for depression: Multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. Br Med J 321(7274):1450-1454.
15. Evinova A, Babusikova E, Straka S, Ondrejka I, Lehotsky J. 2012. Analysis of genetic polymorphisms of brain-derived neurotrophic factor and methylenetetrahydrofolate reductase in depressed patients in a Slovak (Caucasian) population. Gen Physiol Biophys 31(4):415-422.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. 1995. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111-113.
17. Gaunt TR, Rodriguez S, Day IN. 2007. Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8:428.
18. Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, Owen MJ, Craig IW, McGuffin P. 2008. No association with the 5, 10-methylenetetrahydrofolate reductase gene and major depressive disorder: Results of the depression case control (DeCC) study and a meta-analysis. Am J Med Genet Part B 147B(6):699-706.
19. Geisel J, Hubner U, Bodis M, Schorr H, Knapp JP, Obeid R, Herrmann W. 2003. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 41(11):1427-1434.
20. Gilbody S, Lewis S, Lightfoot T. 2007. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 165(1):1-13.
21. Gunn JM, Gilchrist GP, Chondros P, Ramp M, Hegarty KL, Blashki GA, Pond DC, Kyrios M, Herrman HE. 2008. Who is identified when screening for depression is undertaken in general practice? Baseline findings from the diagnosis, management and outcomes of depression in primary care (diamond) longitudinal study. Med J Aust 188(12 Suppl):S119-S125.
22. Gunn J, Elliott P, Densley K, Middleton A, Ambresin G, Dowrick C, Herrman H, Hegarty K, Gilchrist G, Griffiths F. 2013. A trajectory-based approach to understand the factors associated with persistent depressive symptoms in primary care. J Affect Disord 148(2-3):338-346.
23. Hegarty K, Gunn J, Blashki G, Griffiths F, Dowell T, Kendrick T. 2009. How could depression guidelines be made more relevant and applicable to primary care? A quantitative and qualitative review of national guidelines. Br J Gen Pract 59(562):e149-e156.
24. Hong ED, Taylor WD, McQuoid DR, Potter GG, Payne ME, Ashley-Koch A, Steffens DC. 2009. Influence of the MTHFR C677T polymorphism on magnetic resonance imaging hyperintensity volume and cognition in geriatric depression. Am J Geriatr Psychiatry 17(10):847-855.
25. Katon W, Unutzer J, Russo J. 2010. Major depression: The importance of clinical characteristics and treatment response to prognosis. Depress Anxiety 27(1):19-26.
26. Kelly CB, McDonnell AP, Johnston TG, Mulholland C, Cooper SJ, McMaster D, Evans A, Whitehead AS. 2004. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol 18(4):567-571.
27. Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, McPartlin J, Scott JM, Whitehead AS. 2003. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101(7):2483-2488.
28. Kroenke K, Spitzer RL, Williams JB. 2001. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16(9):606-613.
29. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN, Ebrahim S. 2006. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry 11(4):352-360.
30. Licht-Strunk E, van der Windt DA, van Marwijk HW, de Haan M, Beekman AT. 2007. The prognosis of depression in older patients in general practice and the community. A systematic review. Fam Pract 24(2):168-180.
31. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM, Trijbels FJ, Blom HJ. 2001. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 79(9):522-528.
32. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, van Duijn CM. 2008. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 13(8):772-785.
33. Moorthy D, Peter I, Scott TM, Parnell LD, Lai CQ, Crott JW, Ordovas JM, Selhub J, Griffith J, Rosenberg IH, et al. 2012. Status of vitamins B-12 and B-6 but not of folate, homocysteine, and the methylenetetrahydrofolate reductase C677T polymorphism are associated with impaired cognition and depression in adults. J Nutr 142(8):1554-1560.
34. Moran P, Leese M, Lee T, Walters P, Thornicroft G, Mann A. 2003. Standardised Assessment of Personality-Abbreviated Scale (SAPAS): Preliminary validation of a brief screen for personality disorder. Br J Psychiatry 183:228-232.
35. Morris DW, Trivedi MH, Rush AJ. 2008. Folate and unipolar depression. J Altern Complement Med 14(3):277-285.
36. Papakostas GI, Cassiello CF, Iovieno N. 2012. Folates and s-adenosylmethionine for major depressive disorder. Can J Psychiatry 57(7):406-413.
37. Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L, de Hert M, Delespaul P, van Winkel R, Rutten BP. 2011. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability? Brain Behav Immun 25(8):1530-1543.
38. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P, Cuijpers P, De Jong PJ, Van Marwijk HW, Assendelft WJ et al. 2008. The Netherlands Study of Depression and Anxiety (NESDA): Rationale, objectives and methods. Int J Methods Psychiatr Res 17(3):121-140.
39. Potiriadis M, Chondros P, Gilchrist G, Hegarty K, Blashki G, Gunn JM. 2008. How do Australian patients rate their general practitioner? A descriptive study using the General Practice Assessment Questionnaire. Med J Aust 189(4):215-219.
40. Radloff L. 1977. The CES-D Scale: A Self-Report Depression Scale for research in the general population. Appl Psychol Meas 1:385-401.
41. Reif A, Pfuhlmann B, Lesch KP. 2005. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 29(7):1162-1168.
42. Rozen R. 1996. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 19(5):589-594.
43. Rubenstein LV, Rayburn NR, Keeler EB, Ford DE, Rost KM, Sherbourne CD. 2007. Predicting outcomes of primary care patients with major depression: Development of a depression prognosis index. Psychiatr Serv 58(8):1049-1056.
44. Savas S, Liu G. 2009. Genetic variations as cancer prognostic markers: Review and update. Hum Mutat 30(10):1369-1377.
45. Simon GE. 2000. Long-term prognosis of depression in primary care. Bull World Health Organ 78(4):439-445.
46. Spitzer RL, Kroenke K, Williams JB. 1999. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282(18):1737-1744.
47. Stegenga BT, Kamphuis MH, King M, Nazareth I, Geerlings MI. 2012. The natural course and outcome of major depressive disorder in primary care: The PREDICT-NL study. Soc Psychiatry Psychiatr Epidemiol 47(1):87-95.
48. Sunder-Plassmann G, Fodinger M. 2003. Genetic determinants of the homocysteine level. Kidney Int Suppl(84):S141-S144.
49. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. 2004. Folate for depressive disorders: Systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol 18(2):251-256.
50. van Beljouw IM, Verhaak PF, Cuijpers P, van Marwijk HW, Penninx BW. 2010. The course of untreated anxiety and depression, and determinants of poor one-year outcome: A one-year cohort study. BMC Psychiatry 10:86.
51. van Weel-Baumgarten EM, Schers HJ, van den Bosch WJ, van den Hoogen HJ, Zitman FG. 2000. Long-term follow-up of depression among patients in the community and in family practice settings. A systematic review. J Fam Pract 49(12):1113-1120.
52. Ware J Jr, Kosinski M, Keller SD. 1996. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220-233.
53. WHO. 1997. Composite International Diagnostic Interview (CIDI-Auto). Version 2.1. Geneva, Switzerland.
54. Wiesemann C. 1998. The significance of prognosis for a theory of medical practice. Theor Med Bioeth 19(3):253-261.
55. World Health Organization. 1998. The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med 46(12):1569-1585.
56. Young AS, Klap R, Shoai R, Wells KB. 2008. Persistent depression and anxiety in the United States: Prevalence and quality of care. Psychiatr Serv 59(12):1391-1398.
57. Zintzaras E. 2006. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: A meta-analysis of genetic association studies. Psychiatr Genet 16(3):105-115.
58. Zubenko GS, Maher B, Hughes HB III, Zubenko WN, Stiffler JS, Kaplan BB, Marazita ML. 2003. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am J Med Genet Part B 123B(1):1-18.